
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics is poised for success with the potential for strong clinical data results in the next year, which we believe will serve as catalysts for the stock. Despite reporting a loss in Q3 2025, the company's current valuation is attractive and presents significant upside potential. With multiple clinical trials in progress and a billion dollar market potential, Atossa offers high rewards for its high risks, making it a promising investment opportunity with a BUY rating and a 12-month price target of $24 based on a NPV analysis.
Bears say
Atossa Therapeutics is facing financial challenges with its limited pipeline and lack of revenue generation. Despite ongoing clinical trials, the company has yet to bring a product to market and may struggle to obtain necessary funding. The recent appointment of a new CFO may bring some changes, but it remains uncertain if they will be able to turn the company's financial situation around.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares